PRECISE DM DXNCT07111416
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
StatusEnrolling by Invitation
PhaseNot specified
SponsorBrigham and Women's Hospital
Primary completion (estimated)
At risk: Primary completion moved 8 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Apr 1, 2026 to Dec 1, 2026 Show 4 more changesShow less
- Enrolling by invitation only
- Start date changed from estimate of Sep 1, 2025 to Dec 1, 2025
- Eligibility criteria expanded, about 18 words
- Study completion pushed from May 1, 2026 to Mar 1, 2027
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Calculate the Mean Absolute Difference Between A1c-Derived Estimated Average Glucose (eAG) and CGM-Derived eAG
Timeframe: From 1 week after enrollment to the end of their enrollment at either week 5 or week 10
Sites
1 site in 1 country
- Brigham and Women's HospitalBoston, Massachusetts, United States